June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
1 citations
,
October 2019 in “Journal of Thoracic Oncology” Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
March 2005 in “The Nurse Practitioner” 1 citations
,
January 2020 Resveratrol-loaded nanoparticles show promise for lung cancer treatment.
16 citations
,
April 2022 in “PLoS ONE” Certain microRNAs found in normal cells can effectively suppress various cancers.
December 2025 in “Indian Journal of Case Reports” Stopping azathioprine improved hair loss and bone marrow issues.
July 2022 in “SKIN The Journal of Cutaneous Medicine” A new lotion with halobetasol and tazarotene successfully treats acne keloidalis nuchae.
26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.
11 citations
,
January 2019 in “Acta Dermato Venereologica” Omalizumab may cause hair loss.
January 2026 in “Clinical & Translational Oncology” Early intervention and tailored management are crucial for skin side effects in cancer treatments.
March 2026 in “Pharmaceutics” Plant-derived nanovesicles show promise in cancer treatment but need standardized preparation.
141 citations
,
September 2016 in “European Journal of Dermatology” Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.
2 citations
,
December 2023 in “Current Pharmaceutical Biotechnology” Nanocarriers can improve the effectiveness of herbal medicines in treating colorectal cancer.
5 citations
,
July 2024 in “Archives of Dermatological Research” 2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
Acitretin improved monilethrix symptoms temporarily, but they returned after stopping treatment.
February 2014 in “Cancer Research” Recent findings advanced understanding of cancer mechanisms and potential treatments.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
1 citations
,
July 2018 in “Dermatologic Surgery” Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
Dupilumab improved hair and skin in a woman with Netherton syndrome.
July 2025 in “Scientific Reports” Six key genes can predict bladder cancer outcomes and may serve as prognostic biomarkers.